Last reviewed · How we verify

NCT05715502: FocaSaBra

Focal Salvage Brachytherapy Study (FocaSaBra)

Recruiting now NA Last updated 30 April 2025
What this trial tests

NA trial testing brachytherapy in Prostate Cancer in 100 participants. Currently enrolling.

Timeline
1 May 2022
Primary endpoint
31 December 2025
31 December 2028

Quick facts

Lead sponsorThe Greater Poland Cancer Centre
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment100
Start date1 May 2022
Primary completion31 December 2025
Estimated completion31 December 2028
Sites1 location across Poland

Drugs / interventions tested

Conditions studied

Sponsor

The Greater Poland Cancer Centre — full company profile →

Who can join

18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this prospective phase II study is to evaluate the toxicity of salvage partial (focal) prostate brachytherapy in patients after prior radiotherapy (standard teleradiotherapy with / without brachytherapy, hypofractionated, self-reactive HDR / LDR brachytherapy) with local recurrence on the part of the prostate gland.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Salvage low-dose-rate brachytherapy for locally recurrent prostate cancer after definitive irradiation.
    Meraouna Y, Blanchard P, Losa S, Labib A, et al · · 2024 · PMID 39027689 · DOI 10.1016/j.ctro.2024.100809

Verify or expand the search:

Other trials of brachytherapy

Trials testing the same drug.

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

Other The Greater Poland Cancer Centre trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05715502.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing